ClinicalTrials.Veeva

Menu

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

N

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Status and phase

Completed
Phase 2

Conditions

Heart Failure, Congestive
Renal Insufficiency

Treatments

Drug: KW-3902IV

Study type

Interventional

Funder types

Industry

Identifiers

NCT00159614
CKI-203

Details and patient eligibility

About

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stable congestive heart failure
  • Impaired renal function
  • Taking oral loop diuretic

Exclusion criteria

  • Acutely decompensated (unstable) and end stage heart failure
  • Diuretics other than loop diuretics
  • Pregnant or nursing
  • Inability to follow instructions
  • Participation in another clinical trial within past 30 days

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems